Pliant Therapeutics Announces Three Upcoming Presentations at the European Respiratory Society International Congress 2023
August 28 2023 - 4:05PM
Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage
biotechnology company focused on discovering and developing novel
therapeutics for the treatment of fibrosis, today announced three
upcoming presentations at the European Respiratory Society (ERS)
International Congress 2023. The congress will take place in Milan,
Italy from September 9, 2023 to September 13, 2023.
Oral and Poster Presentation Title: Dual αVβ6/αVβ1
integrin inhibitor bexotegrast reduces fibrogenesis in pathological
cell populations present in the fibrotic human lung Date:
Sunday, September 10, 2023 Session: From the transcriptome
landscape to innovative preclinical models in lung diseases Session
Time: 11:40 am CEST
Oral and Late Breaking Poster PresentationTitle: Safety,
tolerability and antifibrotic activity if bexotegrast: Phase 2a
INTEGRIS-IPF Study (NCT04396756)Date: Sunday, September
10, 2023Session: Novel research impacting clinical practice in
interstitial lung diseaseSession Time: 2:15 to 3:30 pm CEST
Late Breaking Poster PresentationTitle: Circulating
ITGB6 levels are elevated in patients with IPF and reduced
following lung transplant Date: Monday, September 11,
2023Session: Towards the identification of new biomarkers in
pulmonary diseasesSession Time: 12:30 to 2:00 pm CEST
The abstracts to the above presentations can be found by
searching the ERS International Congress 2023 Congress
Programme.
About Pliant Therapeutics, Inc.Pliant
Therapeutics is a clinical stage biopharmaceutical company focused
on discovering and developing novel therapies for the treatment of
fibrosis. Pliant's lead product candidate, bexotegrast (PLN-74809),
is an oral, small molecule, dual selective inhibitor of αvß6 and
αvß1 integrins that is in development in the lead indications for
the treatment of idiopathic pulmonary fibrosis, or IPF, and primary
sclerosing cholangitis, or PSC. Bexotegrast has received Fast Track
Designation and Orphan Drug Designation from the U.S. Food and Drug
Administration (FDA) in IPF and PSC and Orphan Drug Designation
from the European Medicines Agency in IPF and PSC. Pliant has
initiated BEACON-IPF, a Phase 2b trial of bexotegrast in IPF.
Pliant has also developed PLN-1474, a small molecule, selective
inhibitor of αvß1 integrin for the treatment of nonalcoholic
steatohepatitis, or NASH with liver fibrosis. Pliant has initiated
a Phase 1 study for its third clinical program, PLN-101095, a small
molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that
is being developed for the treatment of solid tumors. In addition
to clinical stage programs, Pliant currently has a preclinical
program targeting muscular dystrophies. For additional information,
please visit: www.PliantRx.com. Follow us on social media
Twitter, LinkedIn, Facebook and YouTube.
Investor and Media Contact:Christopher
KeenanVice President, Investor Relations and Corporate
CommunicationsPliant Therapeutics, Inc.ir@pliantrx.com
Pliant Therapeutics (NASDAQ:PLRX)
Historical Stock Chart
From Apr 2024 to May 2024
Pliant Therapeutics (NASDAQ:PLRX)
Historical Stock Chart
From May 2023 to May 2024